baber/WOPTO huggingface dataset:
Patent AU-2002345155-B2 (AU)
Title: Screw compressor with switched reluctance motor
Inventor: NICHOL PHILIP
IPC: H02K7/09
Filed: 2002-06-10
Granted: 2007-02-08
Abstract: A screw compressor assembly is provided for compressed gas comprising a screw compressor 10 having a casing 16 and at least one pair of intermeshing helically formed screw rotors 11 and 12 each of which is mounted on a rotor shaft 13, 14 rotatably mounted within the casing by means of bearings 15. Said assembly further comprises a switched reluctance motor 17 comprising a stator 18 attached to the casing 16 and a rotor 19 mounted on one of the motor shafts 13 such that one of the screw rotors 11 is driven directly by the motor. In operation a magnetic field is generated in the motor stator 18 which causes the motor rotor 19 to turn which rotates the driven compressor rotor 11. The motor rotor is displaced relative to the stator by a pre-determined axial distance x such that a resultant magnetic force is provided in an axial direction.
Patent AU-2003206479-B2 (AU)
Title: Antimicrobial composition
Inventor: CHILCOTT CHRISTOPHER NORMAN
IPC: A61K35/644
Filed: 2003-02-21
Granted: 2008-06-12
Abstract: This invention provides novel Streptococcus salivarius, compositions containing same, and use of S. salivarius strains as antimicrobial agents. The strains are bacterial inhibitors with respect to at least S. mutans and/or MS and therefore have a number of therapeutic applications. The applications include but are not limited to forming part of therapeutic formulations for use in controlling, treating, or preventing dental caries.
Patent AU-2003214275-B2 (AU)
Title: Novel therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
Inventor: BLANCO JOSE MANUEL LOPEZ
IPC: A61K31/7056
Filed: 2003-03-20
Granted: 2006-02-09
Abstract: Acadesine (also known as AICA riboside or AICAR) does not inhibit apoptosis in lymphocytes, as it might be expected, but it induces apoptosis in B cells from patients with B-cell lymphoproliferative disorders such as B-cell chronic lymphocytic leukemia (B-CLL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), and Waldenstrom syndrome (WS). T cells are not affected. This makes acadesine and its bioprecursors (eg. its mono-, di- and tri-5'-phosphates) useful as therapeutic agents for B-cell lymphoproliferative disorders in humans. The surprising feature that T cells are virtually not affected means that the side effect (immunosuppression) is minor, what represents a therapeutical advantage of acadesine over cladribine, fludarabine and other nucleosides known in the art.
Patent AU-2003233067-B2 (AU)
Title: Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders
Inventor: GAILLARD PASCALE
IPC: C07D417/06
Filed: 2003-04-25
Granted: 2009-01-08
Abstract: The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation.
Patent AU-2003261264-B2 (AU)
Title: Regulated aptamer therapeutics
Inventor: EPSTEIN DAVID
IPC: C12M1/34
Filed: 2003-07-25
Granted: 2008-12-11
Abstract: Materials and methods of use thereof are presented for the treatment of diabetes and other diseases. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of diabetes disease are presented with methods of administering these therapeutic compositions.
Patent AU-2004238299-B2 (AU)
Title: Wet shaving assembly
Inventor: ORLOFF GLENNIS J
IPC: A45D27/16
Filed: 2004-05-07
Granted: 2008-03-06
Abstract: A shaving assembly (1110) operable in dry shaving environments and wet shaving environments is provided that includes a razor assembly (1114) and a shaving preparation cake (1112). The razor assembly (1114), which includes a razor cartridge (1116) attached to a handle (1118), is operable in dry shaving environments and wet shaving environments The shaving preparation cake (1112) includes an upper surface, a lower surface, one or more side surfaces extending between the upper surface and the lower surface, and an axial bore (1120) extending between the upper surface and the lower surface. The shaving preparation cake (1112) is operable in a wet shaving environment, and is selectively attachable to the razor assembly (1114) for wet shaving environment applications. When the shaving preparation cake (1112) is attached to the razor assembly (1114), the razor cartridge (1116) is disposed within the axial bore (1120) of the shaving preparation cake (1112). The shaving preparation cake (1112) is selectively detachable from the razor assembly (1114) to facilitate use of the razor assembly in dry shaving environment applications
Patent AU-2004292369-B2 (AU)
Title: Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications
Inventor: NICOLAS FLORENCE
IPC: A61K38/21
Filed: 2004-11-19
Granted: 2010-12-09
Abstract: A liquid pharmaceutical formulation (I) for prolonged release of active agent(s) (A) comprises a low viscosity aqueous colloidal suspension of submicron particles of water-soluble, biodegradable polymers (II) carrying hydrophobic groups, non-covalently associated with (A), where on parenteral injection (I) forms a gelled depot for prolonging the duration of (A) release to more than 24 hours. A liquid pharmaceutical formulation (I) for prolonged release of active agent(s) (A) comprises a low viscosity aqueous colloidal suspension (with water as dispersion medium) based on submicron particles (SMP's) of water-soluble, biodegradable polymers (II) carrying hydrophobic groups (HG's), non-covalently associated with (A). On parenteral injection, (I) forms a gelled depot in vivo (at least partially due to physiological proteins), controlling and prolonging the duration of (A) release to more than 24 hours. (I) is liquid under the injection conditions; at physiological temperature and/or pH; and/or in presence of physiological electrolytes at physiological concentrations and/or surfactant(s). Independent claims are included for: (1) a variant of (I) as described above, where the duration of release of (A) is not restricted but the concentration of (II) is sufficiently high to form a gelled depot in vivo in presence of protein(s) after parenteral injection; (2) novel derived products (preferably in powder or gel form), consisting of SMP's formed by non-covalent association of (II) and (A) as above and obtained from (I); and (3) methods of preparation of (I).
Patent AU-2005203698-B2 (AU)
Title: Carrier
Inventor: WEST SIMON MICHAEL
IPC: A61K47/22
Filed: 2005-08-17
Granted: 2009-02-05
Abstract: There is provided a method for improving the efficacy and/or transdermal transport of topically administered pharmaceuticals and pharmacologically active compounds, said method comprising the step of incorporating the pharmaceutical or pharmacologically active compound in a carrier comprising an effective amount of one or more complexes of a phosphate derivative of a lipophilic pharmaceutically acceptable compound.
Patent AU-2005209231-B2 (AU)
Title: Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
Inventor: REEVES PATRICK MICHAEL
IPC: A61K31/519
Filed: 2005-01-20
Granted: 2011-03-17
Abstract: Compositions and methods are provided for using tyrosine kinase inhibitors to treat pathogenic infection. In particular, methods for using Abl-family tyrosine kinase inhibitors to treat pathogenic infection are provided. Infections to be treated according to the present invention include, particularly, those caused by microbial pathogens such as bacteria and viruses.
Patent AU-2005227361-B2 (AU)
Title: Power module cartridge
Inventor: PERRIN DAVID W
IPC: B23K9/00
Filed: 2005-10-26
Granted: 2007-07-12
Abstract: A power module cartridge (12) for a welder (10) includes a chassis tray that is dimensioned to fit inside an external case of the welder (14). The chassis tray includes a fan receptacle, a capacitor receptacle, a rectifier mounting slot and a transformer receptacle. A fan (24) fits into the fan receptacle; a capacitor fits into the capacitor receptacle; a rectifier plate (26) fits into the rectifier mounting slot; and a transformer (30) fits into the transformer receptacle. The chassis tray can also include a clip for receiving a printed circuit board ("PCB"). The PCB can be electrically connected to the aforementioned components. A second chassis tray (22) can fit on the top of each of the components such that the components are sandwiched between the first and second chassis trays (22). A method of manufacturing a welder is also disposed.
Patent AU-2005273487-B2 (AU)
Title: Method and composition for modulation of Systemic Inflammatory Responses Syndrome (SIRS)
Inventor: LOCKER CHAIM
IPC: A61K35/583
Filed: 2005-08-16
Granted: 2011-03-03
Abstract: The present invention relates to pharmaceutical composition comprising animal venom and using same in a method for the treatment of Systemic Inflammatory Response Syndrome (SIRS) and related pathologies.
Patent AU-2005305193-B2 (AU)
Title: Instruments and methods for reduction of vertebral bodies
Inventor: JONES ROBERT J
IPC: A61B17/88
Filed: 2005-11-01
Granted: 2012-02-16
Abstract: A spinal stabilization system may be formed in a patient. In some embodiments, a minimally invasive procedure may be used to form a spinal stabilization system in a patient. Bone fastener assemblies may be coupled to vertebrae. Each bone fastener assembly may include a bone fastener and a collar. The collar may be rotated and/or angulated relative to the bone fastener. Extenders may be coupled to the collar to allow for formation of the spinal stabilization system through a small skin incision. The extenders may allow for alignment of the collars to facilitate insertion of an elongated member in the collars. An elongated member may be positioned in the collars and a closure member may be used to secure the elongated member to the collars. A reducer may be used to achieve reduction of one or more vertebral bodies coupled to a spinal stabilization system.
Patent AU-2006216965-B2 (AU)
Title: A container
Inventor: COONE RYAN J
IPC: B65D43/03
Filed: 2006-02-16
Granted: 2012-06-28
Abstract: The container can be locked into a stack of containers. A container cover locks onto the top of a container base to define a sealed area for storage. Additionally, the bottom of a second container base can be locked onto the top of the cover of a first container. In this fashion, when closed containers are stacked, they form a locked stack that is more structurally rigid and therefore less precarious than a traditional, non-locked container stack. When not in use, the bases can be formed into a nested stack, and their covers can be locked together to form a locked cover stack. The locked cover stack can be locked to either the top or bottom of the nested base stack to form a rigid stack, hi some embodiments, a cover can be turned upside down and its bottom face locked onto the bottom face of a base.
Patent AU-2006243112-B2 (AU)
Title: Lower limb setting compression orthesis in the form of a stocking, sock or panty hose-shaped knitted article
Inventor: ARNAUD GOBET
IPC: A61F13/08
Filed: 2006-04-28
Granted: 2011-08-18
Abstract: The inventive orthesis comprises leg and foot parts. The leg part (10) upwardly extending away from the ankle applies a therapeutic retention pressure on the leg when the orthesis is drawn on. The foot part extending away from an ankle bone (14) to toes (16) and covering the instep (18) is embodied in the form of a foot elastically enveloping part. The size and structure of the foot part mesh are such that, when the orthesis is drawn on, it is equal to: (i) 0 < P < P < P et (ii) P < 36 mmHg, wherein P is the pressure applied to the instep, Pis a pressure applied to the malleoli and P is a therapeutic retention pressure applied to the ankle. In the preferred embodiment, P = 5 mmHg ± 25 %, and P = 0,5.(P + P) ± 25 % .
Patent AU-2006256699-B2 (AU)
Title: Generic radar architecture
Inventor: PHILIPPE ELLEAUME
IPC: H04J3/06
Filed: 2006-06-09
Granted: 2011-09-15
Abstract: The invention relates to general architectures of complex electronic and/or information systems for which exchanges are embodied in the form of irregular data fluxes generated by time-varying processing functions. The aim of said invention is to develop an architecture adapted to electronic systems provided with a plurality of processing nodes, wherein each node carries out a function or a part thereof used by the system. Said architecture is built on a single synchronisation link, which supplies a common synchronisation message containing synchronisation data elements and a simplified heading to all modules, and on a plurality of data exchange asynchronous links each of which makes it possible to exchange data between two individual processing nodes, wherein the exchanged messages comprise the processable data elements accompanied by a generic heading. The generic heading of asynchronous links contains the totality of information items related to the system-operating step to which the exchanged data elements correspond. The synchronous link simplified heading makes it possible to determine a stream of data to which the associated synchronisation information items are applicable. Each processing node comprises means for interfacing with synchronous and asynchronous links. Said invention is particularly suitable to the structure of electromagnetic or acoustical sensors such as radars and sonars.
Patent AU-2006262150-B2 (AU)
Title: PRRS viruses, infectious clones, mutants thereof, and methods of use
Inventor: YUE WANG
IPC: C12N15/86
Filed: 2006-06-23
Granted: 2011-07-21
Abstract: The present invention provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to PRRS viruses such as VR-2332, Lelystad, or others, and optionally further including a deletion in a region of ORFl that encodes the nsp2 polypeptide.
Patent AU-2006306241-B2 (AU)
Title: Dietary fiber formulation and method of administration
Inventor: FALK ANNE L
IPC: A23L33/00
Filed: 2006-10-23
Granted: 2012-02-16
Abstract: The invention provides dietary fiber formulation and related methods for its administration. In one embodiment, the invention provides a dietary fiber formulation comprising: partially-hydrolyzed guar gum (PHGG); and fructooligosaccharides (FOS), wherein the dietary fiber formulation exhibits a prebiotic potential greater than a prebiotic potential of PHGG and FOS individually.
Patent AU-2006334364-B2 (AU)
Title: Imidazo (1,2-a)pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof
Inventor: ANTONIO GUGLIETTA
IPC: C07D471/04
Filed: 2006-12-21
Granted: 2011-09-29
Abstract: The invention provides novel imidazo[1,2-a]pyridin- 3-yl-acetic acid hydrazides of formula (I) wherein R, R and R have different meanings, and pharmaceutically acceptable salts, polymorphs, hydrates, tautomers, solvates and stereoisomers thereof. Compounds of formula (I) are useful for treating or preventing, in a human or non-human mammal, diseases associated with GABA receptors modulation, anxiety, epilepsy, sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. The invention also provides synthetic processes for preparing said compounds.
Patent AU-2006337617-B2 (AU)
Title: Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
Inventor: REITZ ALLEN B
IPC: A61P3/06
Filed: 2006-12-19
Granted: 2013-02-07
Abstract: The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) or formula (II) as herein defined. The present invention is further directed to methods of treatment comprising co-therapy with an anti-diabetic agent, and anti-lipid agent and/or an anti-obesity agent.
Patent AU-2007213494-B2 (AU)
Title: Consolidating agent emulsions and associated methods
Inventor: RUSH THOMAS E
IPC: C09K8/62
Filed: 2007-02-07
Granted: 2012-01-19
Abstract: Methods comprising: providing a consolidating agent emulsion composition that comprises an aqueous fluid, a surfactant, and a consolidating agent; and coating at least a plurality of particulates with the consolidating agent emulsion to produce a plurality of consolidating agent emulsion coated particulates. Methods comprising: providing a treatment fluid comprising a consolidating agent emulsion comprising an aqueous fluid, an amine surfactant, and a consolidating agent; and introducing the treatment fluid into a subterranean formation. Methods comprising the steps of: coating a plurality of particulates with a consolidating agent emulsion to produce consolidating agent emulsion coated particulates; providing a treatment fluid comprising an aqueous fluid, a surfactant, and a consolidating agent; introducing the treatment fluid into a subterranean formation. Consolidating agent emulsion compositions comprising: an aqueous fluid; a surfactant; and a consolidating agent comprising a non-aqueous tackifying agent or resin.
Patent AU-2007218396-B2 (AU)
Title: Improved preparation of molecular imprinted polymers
Inventor: KROGH NICOLAS OTTO
IPC: B01J20/26
Filed: 2007-02-21
Granted: 2011-07-28
Abstract: One aspect is a method for improved preparation of molecular imprinted polymer (MIP) particles, where initial compositions comprising insoluble MIP particles are enriched for those MIP particles that bind a particular target molecule, thus excluding non-binding and weakly binding particles from the final composition. Enrichment is typically accomplished via use of chromatographic methods capable of separating particulate material or by means of agglutination. Another aspect is preparation of improved insoluble MIPs by use of extended micronization of raw MIP particles with a view to expose a large number of binding sites per mass unit of MIP particles. In preferred embodiments the two aspects are combined. The resulting improved MIPs may be used for diagnostic, analytical and therapeutic purposes, notably as orally administered drugs which can bind substances such as cholesterol and bile acids and bile acid salts in the gastrointestinal tract.
Patent AU-2007220893-B2 (AU)
Title: Method and apparatus for producing quantum entanglement and non-local effects of substances
Inventor: HU HUPING
IPC: H04B14/00
Filed: 2007-02-17
Granted: 2012-06-07
Abstract: A method and apparatus are disclosed which produce quantum entanglement and non-local effects of various substances on responsive targets such as biological and/or chemical systems through quantum entanglement. In one broad embodiment, the apparatus includes a quantum entanglement generating source, said source emitting a plurality of quantum- entangling members such as photons when said source operates; and a substance disposed adjacent to said source, said substance being responsive to said members; such that when said source emits said members which pass through said substance and a biological system, said members first quantum-entangle with quantum entities in said substance, then travel to said biological system such as a human body and subsequently entangle with quantum entities inside the biological system producing non-local effect of the substance on said biological system through quantum entanglement.
Patent AU-2007234843-B2 (AU)
Title: Inhibitors of histone deacetylase
Inventor: MALLAIS TAMMY
IPC: C07D417/12
Filed: 2007-04-05
Granted: 2013-07-11
Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds which are derivatives of benzamide and suitable in methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions .
Patent AU-2007242042-B2 (AU)
Title: A method and system for measuring organisational culture
Inventor: BASSER IAN
IPC: G06Q10/00
Filed: 2007-01-09
Granted: 2012-07-05
Abstract: A method for measuring the culture of an organisation includes establishing (202) a plurality of categories relating to the culture of the organisation, said categories being grouped into a plurality of clusters, wherein each cluster includes a selected one or more of the categories which relate to a predetermined aspect of organisational culture. Information is provided (206) by a plurality of individuals associated with the organisation, regarding each of said individual's personal experience of the culture of the organisation in relation to each of the categories. The received information is processed (208) to determine, with regard to each category, a corresponding category grade representing an extent to which the experience of the individuals is either positive or negative. A chart is generated (210) which includes graphical representations of each one of the clusters, each cluster graphical representation including graphical representations of the category grades determined for the categories grouped within the corresponding cluster. The method enables feedback to be obtained regarding the organisational culture from a variety of different individuals associated with the organisation, and the grouping of cultural categories into clusters facilitates a more effective appreciation of the contribution made by those aspects to the overall culture of the organisation. The chart may enable rapid visual assimilation of the overall culture of the organisation, with each cluster representing a specific and carefully chosen aspect of organisation culture. The method is preferably implemented as an online system, wherein information may be gathered from individuals, and results presented, via a convenient web-based interface.
Patent AU-2007272008-B2 (AU)
Title: Teat rubber with shock-absorbing properties
Inventor: FRENSER REINHARD
IPC: A01J5/08
Filed: 2007-07-10
Granted: 2012-01-19
Abstract: The invention relates to a teat rubber for use on a milking cup that has a head part with an insertion opening for an animal's teat. Connected to the head part is a shank part. Arranged underneath the head part is a holding rim, which surrounds the shank part at a distance from it. The teat rubber according to the invention is distinguished by the fact that the holding rim has in its inner lateral surface at least one recess extending substantially in the circumferential direction of the holding rim, the recesses of the end face of the sleeve preferably being formed such that they are opposite one another.
Patent AU-2007277146-B2 (AU)
Title: Compositions and methods for diagnosing patients with acute atherosclerotic syndromes
Inventor: MICHAEL IVERSON G
IPC: G01N33/564
Filed: 2007-07-26
Granted: 2011-10-20
Abstract: The present invention is in the field of autoimmunity. More specifically, the present invention relates to the detection of autoantibodies to domain 4 of beta 2-glycoprotein I (β-GPI) as an indicator for atherosclerosis.
Patent AU-2007285556-B2 (AU)
Title: Well treatment
Inventor: WAT REX
IPC: C09K8/528
Filed: 2007-08-16
Granted: 2012-08-09
Abstract: The present invention provides a method for increasing the retention of a scale inhibitor within a hydrocarbon producing system (e.g. a subterranean formation), said method comprising contacting said system with a polymer formed from a diallyl ammonium salt and with said scale inhibitor, wherein said polymer formed from a diallyl ammonium salt has a molecular weight of greater than 50,000 (e.g. a molecular weight of 55,000 to 2,000,000).